Samenvatting
Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai–Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcoma.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 228-232 |
Aantal pagina's | 5 |
Tijdschrift | International Journal of Hematology |
Volume | 109 |
Nummer van het tijdschrift | 2 |
DOI's | |
Status | Gepubliceerd - 20 feb. 2019 |
Extern gepubliceerd | Ja |